title: Postoperative analgesia after preincisional administration of remifentanil.
abstract: OBJECTIVE
  The aim of this study was to assess postoperative analgesia after preincisional and postincisional administration of remifentanil.
  
  
  METHODS
  Randomized trial, 24 hours.
  
  
  METHODS
  University hospital, hospitalized care.
  
  
  METHODS
  48 adult patients scheduled for lumbar vertebral surgery.
  
  
  METHODS
  in group R5, patients received an infusion of 0.2 microg kg(-1) min(-1) remifentanil over 5 minutes, followed by a break of 15 minutes before anesthesia was started. Anesthesia was induced by infusion of 0.25 microg kg(-1) min(-1) remifentanil and a bolus of 1.5 microg kg(-1) propofol, followed by a continuous infusion of 2 to 3 microg kg(-1) h-1 propofol and 0.25 microg kg(-1) min(-1) remifentanil until end of anesthesia. In group R20, patients received 0.05 microg kg(-1) min(-1) remifentanil over 20 minutes before the induction of anesthesia. In group RL, anesthesia was induced and maintained with propofol. After surgery began, a remifentanil infusion of 0.5 microg kg(-1) min(-1) was given for 50 minutes, then reduced to 0.25 microg kg(-1) min(-1). The total remifentanil doses were similar in the 3 groups.
  
  
  METHODS
  patients used patient-controlled analgesia (piritramide) for postoperative pain management. They recorded pain on a numeric rating scale every half hour.
  
  
  METHODS
  Kruskal-Wallis test, pairwise Mann-Withney U-test, orthogonal polynomials (pain scores).
  
  
  RESULTS
  PATIENTS given postincisional remifentanil (RL) had the slowest decrease in postoperative pain scores (p<0.01) and the highest cumulative piritramide consumption (p<0.08).
  
  
  CONCLUSIONS
  The preincisional administration of remifentanil followed by a continuous infusion of 0.25 microg kg(-1) min(-1) appears to reduce pain scores and piritramid consumption when compared with a postincisional regimen.
authors.affiliation: Department of Anaesthesiology, Schleswig-Holstein University Hospital, Campus Lbeck, Lübeck, Germany. klaus.gerlach@medinf.mu-lubeck.de
authors.forename: K
authors.initials: K
authors.lastname: Gerlach
authors.forename: T
authors.initials: T
authors.lastname: Uhlig
authors.forename: M
authors.initials: M
authors.lastname: Hppe
authors.forename: T
authors.initials: T
authors.lastname: Khirt
authors.forename: L
authors.initials: L
authors.lastname: Saager
authors.forename: P
authors.initials: P
authors.lastname: Schmucker
mesh_terms: D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy / Q000517:prevention & control*; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D010892:Pirinitramide / Q000008:administration & dosage / Q000627:therapeutic use; D011229:Preanesthetic Medication; D011446:Prospective Studies; D000077208:Remifentanil
chemical_list: D000701:Analgesics, Opioid; D010880:Piperidines; D010892:Pirinitramide; D000077208:Remifentanil